SenzaGen AB engages in the development of in vitro test methods for prediction of chemical and protein sensitizers. It offers services for assessment of sensitizers for industry and regulatory purposes, using its proprietary technology called GARD (Genomic Allergen Rapid Detection). It serves clients in cosmetic, chemical, pharmaceutical, and food industries. The company was founded by Malin Marie Lindstedt and Carl Arne Krister Borrebaeck on August 18, 2010 and is headquartered in Lund, Sweden.